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Department of Biomedical Engineering, Columbia University, New York, New YorkABSTRACT Currently, many diabetic cardiomyopathy (DC) studies focus on either in vitro molecular pathways or in vivo
whole-heart properties such as ejection fraction. However, as DC is primarily a disease caused by changes in structural and
functional properties, such studies may not precisely identify the influence of hyperglycemia or hyperlipidemia in producing spe-
cific cellular changes, such as increased myocardial stiffness or diastolic dysfunction. To address this need, we developed an
in vitro approach to examine how structural and functional properties may change as a result of a diabetic environment. Particle-
tracking microrheology was used to characterize the biomechanical properties of cardiac myocytes and fibroblasts under hyper-
glycemia or hyperlipidemic conditions. We showed that myocytes, but not fibroblasts, exhibited increased stiffness under
diabetic conditions. Hyperlipidemia, but not hyperglycemia, led to increased cFos expression. Although direct application of
reactive oxygen species had only limited effects that altered myocyte properties, the antioxidant N-acetylcysteine had broader
effects in limiting glucose or fatty-acid alterations. Changes consistent with clinical DC alterations occur in cells cultured in
elevated glucose or fatty acids. However, the individual roles of glucose, reactive oxygen species, and fatty acids are varied,
suggesting multiple pathway involvement.INTRODUCTIONCardiovascular diseases account for ~80% of deaths asso-
ciated with diabetes mellitus, primarily through coronary
artery disease (1). However, a relatively new clinical entry,
termed diabetic cardiomyopathy (DC), produces heart
failure in diabetic patients independently of coronary artery
disease or hypertension (2,3). In DC, hyperglycemia
and hyperlipidemia are thought to produce structural
and biochemical alterations leading to major functional
changes in the myocardium, which can lead to diastolic
and systolic dysfunction, and eventually to heart failure
(4–6). Early-stage alterations include hypertrophy, calcium
mishandling, apoptosis, excessive reactive oxygen species
(ROS) production, and increased collagen production by
fibroblasts (7–13). Although many of the signs of DC
have been characterized, disease progression is not well
understood, particularly at the early stage of the condition,
thus limiting the ability of researchers to develop treatment
options.
Currently, the majority of DC studies focus either on
in vitro molecular pathway studies or in vivo whole-heart
measurements. However, as DC is primarily a disease of
changes in structural and functional properties in mecha-
nically active tissue, these studies incompletely delineate
potential biomechanical factors underlying these changes.
In particular, we wish to isolate the effects of elevated
glucose or fatty acids on the cardiac myocytes themselves.
In vivo, this would be difficult, as systemic changes may
result in, for example, alterations in release of compounds
from noncardiac tissue that affect the heart. Therefore, weSubmitted October 29, 2013, and accepted for publication April 28, 2014.
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cell structural and functional properties. For example,
increased myocardial stiffness, which is a major contri-
butor to diastolic dysfunction, is currently associated with
increased collagen production in the heart (14,15). How-
ever, diastolic dysfunction can occur in DC before signifi-
cant collagen accumulates (16). Thus, it is possible that
cellular alterations, rather than cardiac fibrosis, contribute
to diastolic dysfunction.
Our hypothesis is that alterations to cellular biomechan-
ical properties, as well as key biomechanically linked path-
ways (hypertrophy), occur at the cardiac cellular level in
response to the diabetic conditions of hyperglycemia or
hyperlipidemia. For example, increased cardiac cell stiff-
ness could contribute to early-stage increases in myocardial
stiffness before the later stages of diabetic heart failure (17).
In testing this hypothesis, we isolated the effects of direct
diabetic conditions from potential extracardiac influences.
To assess whether cardiac-specific changes occur, and
whether they are consistent with DC progression, we first
deployed particle-tracking microrheology in cardiac myo-
cytes, fibroblasts, and coculture of myocytes and fibroblasts
to assess the effects of elevated glucose or PA on cellular
biomechanical properties. For the coculture assay, myocytes
and fibroblasts were plated in bilayers to better mimic the
complex layered structure of the heart, and to more accu-
rately assess the effects of DC conditions on cardiac cell
mechanical properties. In addition, by comparing the
mechanical properties of cardiac cells in a cocultured
bilayer against their properties in a monolayer, we can
assess whether the structural and biochemical interactions
between the two types of cell have significant impact on
their mechanical properties.http://dx.doi.org/10.1016/j.bpj.2014.04.040
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ating biomechanical changes associated with diabetes.
Elevation of ROS can lead to cellular damage by oxidation
by interfering with nitric oxide (NO) and by modulating
redox signaling pathways (18). Oxidative stress is impli-
cated in all stages of DC, including hypertrophy, fibrosis,
and contractile dysfunction (19). We also assessed the
effects of the antioxidant N-acetylcysteine (NAC) toward
reversing changes in cell biomechanical properties (7,20).
Finally, we assessed the role of diabetic culture conditions
on the hypertrophic indicator cFos, which is a key regu-
lator of cardiac hypertrophy and may be implicated in
DC progression (21,22). We found that there are sig-
nificant cell-level alterations that are consistent with DC
progression, but that the precise role of glucose versus
fatty acids, and of ROS, in mediating these alterations,
is not clear-cut.METHODS
Cell culture
Unless otherwise specified, components were acquired from Life Technol-
ogies (Norwalk, CT).
Primary neonatal rat cardiomyocytes (CMs) were obtained from
minced hearts after euthanasia via decapitation and were cultured using
M199 containing 10% neonatal calf serum (NCS), penicillin/streptomyo-
cin (PS), 0.1 mM 5-bromo-2-deoxyuridine (BrdU) (Sigma, St. Louis,
MO), and 0.2 mM epinephrine (Sigma) (CM plating media), and were
incubated at 37C and 1% CO2. For all high-glucose experiments, except
where specified, on the day after the isolation, the medium was replaced
with M199 containing 5% NCS, PS, and BrdU, with either 5.5 mM (low
glucose (LG)) or 30.5 mM D-Glucose (high glucose (HG)) (Sigma). The
myocytes were then cultured for 2 days before the start of experiments.
The 0.5 mM palmitic acid (PA) and BSA-only medium was made accord-
ing to a previously established protocol (23). In brief, PA (Sigma) was
dissolved in ethanol to a concentration of 195 mM before being diluted
in LG (5.5 mM) M199 to its final concentration (0.5 mM). As a vehicle
for the PA, fatty-acid-free BSA was also added to the medium at a 1:6
molar ratio of the PA (23). The medium was supplemented with 20%
NCS, PS, and BrdU. Unless otherwise stated, cells used in the high-
fatty-acid experiments were treated with either 0.5 mM PA or BSA-
only control medium for 24 h before data were taken. The media was
supplemented with 20% fetal calf serum in all cases for CMs used for
the cFos western blot, as cFos levels were not detectable with 5%
NCS. For NAC (Sigma) treatment, NAC was added to media at concen-
tration of 1uM. For the hydrogen peroxide (HP) experiments, CMs were
treated with HP in LG control media for 24 hr prior to imaging or cell
lysis (for immunoblotting).
Cardiac fibroblasts (CFs) were obtained via the same isolation as the
CMs and cultured using Dulbecco’s modified Eagle’s medium containing
10% fetal calf serum and PS, and were incubated at 37C and 5% CO2.
When the CFs were ~90% confluent, they were treated with serum-free
media for 2 h to render them quiescent (to ensure that all CFs were treated
with HG/PA for equivalent time). Except where noted, the CFs were then
treated with either HG or high fatty acid media (same as CM media,
except with Dulbecco’s modified Eagle’s medium in place of M199 and
with no serum) for 48 and 24 h, respectively, before experiments were
begun. This investigation conforms to the Guide for the Care of Use of
Laboratory Animals as approved by the Columbia Institute of Compara-
tive Medicine.Particle-tracking microrheology experimental
setup for monolayer
For cardiac myocyte and cardiac fibroblast monolayers, dishes were seeded
with 1 mm fluorescent probes (Life Technologies) 24 h before the start of
experiments. Due to the fragile nature of the cardiac myocyte monolayer,
the fluorescent probes were introduced to the cells via endocytosis. Other
techniques, such as microinjection and blast injection, were found to
cause too much damage to the cell or monolayer to be used for the study.
Although endocytosis does introduce the possibility of active motion via
vesicle formation, Jonas et al. found that neutralization of vesicles via
chloriquine had no significant effect on mechanical properties in an endo-
cytosis-based microrheology study (24). To arrest spontaneous contraction,
myocytes were treated with 100 mM KCl (Sigma) in Hank’s buffered salt
solution (HBSS) without calcium or magnesium for 1 h before the start
of experiments. Both cardiac myocytes and fibroblasts were maintained
at 37C during imaging. Bead trajectories were acquired for ~1 min at
16 Hz using a 100 (1.3 NA) objective.Particle-tracking microrheology analysis for
monolayers
Beads were tracked and their trajectory analyzed as previously described
(25,26). Briefly, trajectories were extracted using a custom multiple-parti-
cle-tracking MATLAB (The Mathworks, Natick, MA) program (25,26).
The change in position of particles was tracked over all frames, correcting
for whole-field shifting (motion of the stage or dish). The mean-squared
displacement (MSD) was obtained by averaging over the squared displace-
ments of all particles at various time lags:
Dr2ðtÞ ¼ ðrðt þ tÞ  rðtÞÞ2
t
;
where r(t) describes the particle’s two-dimensional trajectory, and t corre-
sponds to time lag. The MSDs for each bead for a given experimental
condition were then averaged.
Extracted values of averaged MSD (including the standard error) were
compared at three different time lags (0.2 s, 1 s, and 5 s), which were chosen
to represent the data across low, moderate, and high frequencies. MSD
magnitudes at the bottom and top layer at specified time lags were
compared using Student’s t-test.Particle-tracking microrheology experimental
setup for bilayers
To model cardiac tissue in vitro, we deployed a bilayer plating culture using
cardiac myocytes and cardiac fibroblasts to engage heterocellular interac-
tions. For these bilayers, cardiac fibroblasts were plated on top of cardiac
myocytes (myocytes on top of fibroblasts were unstable). To obtain this
bilayer, CMs were first plated on collagen-coated coverslips. After 1 day,
the CMs were seeded with 1 mm diameter fluorescent beads and allowed
to incubate overnight. On the second day, CFs were plated on top of the
CM monolayer, along with additional fluorescent beads. The bilayers
were imaged 1 day after plating the CFs. To arrest spontaneous contraction,
bilayers were treated with 100 mMKCl in HBSS without calcium and mag-
nesium for 1 h before cell imaging.
For HG experiments, both CMs and CFs were fed low or HG media on
the first day after isolation (CFs in separate flask), so that the bilayer was
treated for 2 days with the appropriate media. For high-fatty-acid experi-
ments, high-PA or BSA-only medium was added at the time of CF plating.
During data acquisition, bead trajectories were acquired for the top layer or
bottom layer of cells without explicit identification of the exact cell type.
However, our previous work on bilayer plating suggests that CFs on top
of CMs are stable in this configuration, whereas if they were swapped,
the bilayers tend to lift from the substrate when treated with KCl.Biophysical Journal 106(11) 2322–2329
2324 Michaelson et al.Mirorheological data for bilayers were acquired using HiLo-thresholded
analysis as previously reported (25).Atomic force microscopy
Atomic force microscopy (AFM) was used to compare the stiffness of car-
diac myocytes plated on collagen-coated glass coverslips. To arrest sponta-
neous contraction, myocytes were treated with 100 mM KCl in HBSS
without calcium and magnesium for 1 h before cell indentation. An AFM
(Bruker, Santa Barbara, CA) mounted on an inverted light microscope
(Olympus IX81, Center Valley, PA) was used to measure the elastic moduli
of the cells. The cantilever probe used was a silicon-nitride DNP probe
(Bruker) with a pyramid-shaped tip and a nominal spring constant of
0.12 N/m. Each cell was indented at 1 Hz in five different locations to
find the average Young’s modulus for the cell.
The deflection-versus-displacement data were then fit to an 8th-order
polynomial (27). The contact point was identified as the first point at which
the first and second derivatives were greater than an empirically determined
threshold (27). The force was calculated as the product of the cantilever
spring constant and the cantilever deflection. We then calculated the
point-wise elastic modulus (28) using the equation
E ¼ Fð1 v
2Þ
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when DRðb2=RÞ. For this formulation, D is the indentation depth, 2f is
the tip angle, b is the radius at which the tapered sides transition into a
spherical tip R (set equal to b ¼ Rcosf), and m ¼ 21/2/p for a pyramid-
shaped probe. The contact radius (a) was found by numerically solving
the equation
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R
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¼ 0;
where n ¼ 23/2/p for a pyramid-shaped probe. Elastic modulus values were
statistically compared using Student’s t-test.ROS assay
Intracellular ROS generation was measured with 5(and 6)-chloromethyl-
20,70-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA).
CMs were plated in a 96-well plate. After 2 days, the cells were incubated
with HBSS containing 10 mM CM-H2DCFDA at 37C for 30 min.
After 30 min, the cells were washed with warm HBSS three times, and
serum-free medium (with various treatments) was added to the wells.
The average fluorescence (490 nm excitation, 520 nm emission) for
each cell condition was measured with a microplate reader (BioTek,
Winooski, VT).Biophysical Journal 106(11) 2322–2329Immunoblotting
Immunoblotting was performed on cells lysed in standard RIPA lysis buffer
(Millipore, Billerica, MA) containing 500 nM phenylmethanesulfonyl fluo-
ride, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, and protease inhibitor cocktail (all from Sigma). Samples
were solubilized in LDS sample buffer supplemented with 5% w/v 2-
mercaptoethanol (Sigma). Total protein concentration was determined by
Bradford assay (Sigma). Soluble fractions containing equal amounts of
total protein were separated using sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred onto PVDF membranes (Millipore).
Immunoblotting was performed with goat anti-mouse antibodies for
cFos (Abcam, Cambridge, MA) (1:250) and TXNIP (MBL International,
Woburn, MA) (1:400), followed by horseradish-peroxidase-conjugated
goat anti-mouse secondary antibody (Biorad, Hercules, CA) (1:1000). Blots
were developed with ECL reagents (Perkin Elmer, Waltham, MA) and
imaged using a FUJI imaging unit (Fujifilm, Tokyo, Japan). Relative
band intensities in immunoblotting images were quantified using ImageJ,
with values normalized to loading control (Beta-tubulin, 1:1000, Sigma).RESULTS
Diabetic culture conditions stiffen CMs
but not CFs
We first assessed whether hyperglycemic and hyperlipi-
demic conditions associated with diabetes affected the
biomechanical properties of cardiac cells. We quantified
the rheological properties of CMs using particle-tracking
microrheology and found that elevated glucose diminished
the MSD of CMs at moderate and high time lags (i.e., mod-
erate and low frequencies (Fig. 1 A)). Since diminished
MSD is associated with more stiff and/or more viscous
properties, these results suggest that diabetic conditions
stiffen CMs. Extraction of the complex modulus for the
HG indicates that HG-treated myocytes exhibited a larger
storage modulus than the control cells over all frequencies,
with increased loss modulus at lower frequencies, decreased
loss modulus at higher frequencies, and little change at mid-
range frequencies. Elevated fatty-acid treatment with PA
resulted in significantly diminished MSDs at all examined
frequencies (Fig. 1 B). The PA-treated CMs exhibited
increased storage modulus and loss modulus over all exam-
ined frequencies. Either glucose or fatty acids altered pas-
sive cell biomechanical properties in a manner consistent
with DC. However, fatty-acid treatment exhibited more
consistent alterations compared to glucose, which exhibited
frequency-dependent effects.
Microrheological results were confirmed using AFM at
1 Hz (Fig. 2, A and B). Hyperglycemic conditions increase
the elastic modulus from 7.495 0.87 to 11.555 1.24 kPa,
and hyperlipidemic conditions increase the elastic modulus
from 8.68 5 0.70 to 11.23 5 1.00 kPa. Further work was
done using microrheology alone, since microrheology pro-
vides frequency-dependent information for the same cell
with a single, passive readout and permits characterization
of cell bilayers. Because of the possibility that glucose or
fatty-acid treatment would lead to changes in cell mechanics
FIGURE 1 Bar plots of MSDs (nm2) of cardiac
myocyte monolayers (A and B), cardiac fibroblast
monolayers (C and D), and cardiac myocyte/fibro-
blast bilayers (E and F) treated with HG (left col-
umn) or high-fatty-acid conditions (right column)
at a range of time lags. (A and B) For monolayers,
HG-treated myocytes have a significantly lower
MSD at midrange and high time lags (A), whereas
high-fatty-acid-treated myocytes have a signifi-
cantly lower MSD over the entire range of time
lags (B). (C and D) Neither HG treatment (C) nor
PA treatment (D) has a significant effect on the
MSD of CFs compared to control. (E) For the
glucose-treated bilayer, HG treatment induces a
significant increase in MSD at the bottom layer
(consisting primarily of CMs) over the entire range
of time lags. At the top layer (consisting primarily
of CFs), HG treatment produces no significant
change in MSD. (F) For the PA-treated bilayer,
high PA treatment induces a significant increase
in MSD at the bottom layer over the entire range
of time lags. At the top layer, high PA treatment
produces no significant change in MSD. Data
are compared using Student’s t-test (*p < 0.05,
**p < 0.01, ^p < 0.001).
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tion, we performed actin and talin staining on CMs under
control and diabetic conditions. Results indicated no overt
differences in actin or talin staining among the four condi-
tions (Fig. 2 C).
We next examined CFs and found that their biomechan-
ical properties were mostly invariant to glucose and fatty
acid concentration (Fig. 1, C and D). No significant differ-
ences were observed across all examined frequencies.
We then used a coculture condition by plating cardiac
fibroblasts atop cardiac myocytes to better mimic cell-
cell interactions in vivo. The bottom layer (primarily
CMs) exhibited diminished MSD across all examined
time lags/frequencies under either elevated glucose or
PA treatment, and the top layer (primarily CFs) was not
significantly altered (Fig. 1, E and F). As these results
compare relatively well with the results from the mono-
layer study, we can assume that although some infiltration
may have occurred, they did not significantly alter the rela-
tive changes in mechanical properties between control andDC conditions. However, with bilayer plating, there were
a few notable changes in significance and MSD magni-
tude. First, the bottom-layer MSD was now significantly
different across all time lags, including at 0.2 s, which
was not the case in a plain CM monolayer. Second, the
control MSD was elevated in the bilayer platings compared
to monolayer platings, suggesting that the use of bilayers
alters cell biomechanical properties even at baseline.
Thus, although cardiac fibroblasts may not directly alter
their own characteristics, they likely still regulate CM
properties.ROS treatment does not alter CM stiffness
Elevated ROS is thought to be a key mechanism underlying
the progression of DM, and many diabetes studies examine
the role of ROS in metabolic pathways. Because both
hyperglycemia and hyperlipidemia affected CM properties,
we next assessed the potential role of ROS in stiffening
these cells. Our results indicated that hydrogen peroxideBiophysical Journal 106(11) 2322–2329
FIGURE 2 (A and B) AFM measurements on HG-treated cardiac myo-
cytes compared to LG controls (A) and on CMs treated with 0.5 mM pal-
mitic acid (PA) compared to BSA-only controls (B). Both the HG- and
high-PA-treated myocytes experience a significant increase in elastic
modulus compared to controls (p < 0.05). A double stain using phalloidin
to label actin (green) and anti-talin antibodies to label talin (red) demon-
strated no overt differences in stress fiber or talin morphologies or localiza-
tion under different glucose or fatty acid conditions (C). To see this figure in
color, go online.
2326 Michaelson et al.(HP) dosing at 10 mM did not lead to significant changes in
cell stiffness, since the MSD (and consequently the G’ and
G’’) was not significantly altered under ROS dosing (Fig. 3).
Much higher concentrations of HP were avoided due to
inimical effects on cells.FIGURE 3 Bar plot of the MSD (nm2) of cardiac myocyte monolayers
treated with 10 mM HP compared to treatment with control medium.
Hydrogen peroxide treatment does not appear to directly affect the mechan-
ical properties of cardiac myocytes.
Biophysical Journal 106(11) 2322–2329Diabetic culture conditions upregulate cFos
expression
Another early alteration in DC is the upregulation of hyper-
trophic pathways. Dosing with HG did not cause a signif-
icant change in cFos levels (p > 0.05, Fig. 4, A and B).
However, elevated PA exposure significantly increased in
cFos, and this increase was reversed by NAC treatment,
suggesting that ROS may be involved in cFos regulation
in DC (p < 0.05; Fig. 4, C and D). When we dosed with
HP, only the highest concentration (50 mM) led to elevated
cFos, and cells appeared unhealthy at that dose (p < 0.05,
Fig. 4, E and F). Treatment with NAC reversed the HP-
induced elevations of cFos (Fig. 4, G and H). Signaling
changes associated with diabetic conditions may be influ-
enced more by fatty acid elevation than by the effects of
glucose or ROS alone.DISCUSSION
We examined the biomechanical, contractile, and hyper-
trophic properties of cardiac cells exposed to in vitro condi-
tions simulating diabetes. We found that hyperglycemia
and hyperlipidemia led to increased stiffness in cardiac
myocytes, but not in fibroblasts. These data are consistent
with in vivo experiments and epidemiological data, which
showed an increase in myocardial stiffness early in the
pathogenesis of DC (29,30). Although this increase in myo-
cardial tissue stiffness is likely influenced by increased
collagen production of fibroblasts (13), along with the fibro-
tic replacement of apoptotic/necrotic cells (11), the results
presented here suggest that at least some of the increased
stiffness in diabetic hearts may be due to an increase in
the stiffness of cardiac myocytes themselves at the cellular
level. Although the changes in stiffness are not dramatic,
they may be enough to cause or contribute to increased
cardiac workload over time, leading to DC progression. In
contrast, there was no significant change in the mechanical
properties of cardiac fibroblasts; however, the presence of
fibroblasts in the bilayer plating revealed behavior that was
not apparent in the comparably simple monolayers, such as
the increased MSD in both cell types when plated together,
and the changes to CM properties at low time lags. Thus,
in addition to their role in regulating extracellular matrix
production, CFs may play an indirect regulatory role in
establishing the stiffness of cardiac cells.
Interestingly, treatment with 10 mMHP had no significant
effect on CM mechanical properties or cFos levels, suggest-
ing that ROS may have only a limited effect on cardiac cell
structural properties. Further, although glucose did affect
cell stiffness and contractile dysfunction, it did not alter
cFos levels either. Thus, the effects of individual compo-
nents of glucose, PA, and ROS appear to be multifaceted:
different symptoms arise from different, specific, causes.
Our findings are consistent with previous literature on
FIGURE 4 (A and B) cFos levels between LG control and HG-treated CMs with and without NAC had a variable nonsignificant response, with HG-treated
CMs experiencing a nonsignificant increase in ROS levels and NAC producing a variable response in both LG control and HG-treated cells. (C and D) PA-
treated CMs see a significant increase in cFos expression, suggesting the presence of hypertrophy in these cells. NAC produces a nonsignificant decrease in
cFos expression in PA-treated CMs. (E and F).Finally, cFos levels were measured for CMs treated with varying concentrations of HP. cFos levels were found
to increase with increasing levels of HP, though these levels were not significantly larger than those measured for controls except in the case of CM treatment
with 50 mM HP. (G and H) Treatment with NAC reduces ROS-induced cFos increase to control levels. The results are shown as the mean5 SE. Statistical
comparisons were made by one-way analysis of variance with a Tukey post-test (*p < 0.05; ^ p < 0.001).
Diabetes and Cardiac Biomechanics 2327DC demonstrating diastolic dysfunction, cFos elevation, and
the potentially therapeutic effects of compounds with anti-
oxidant effects on DC (22,31).
To determine whether HG and high fatty acid directly
increased cell ROS levels, we measured ROS levels with
HG or PA treatment (Fig. S1 in the Supporting Material).
The ROS assay did not show a clear change in ROS levels
with HG or PA relative to their controls. However, this
does not mean that there is no elevation in ROS. The assay
was unable to detect ROS up to concentrations that clearly
start to affect the viability of cells; at 10 mM, for example,
diastolic dysfunction was elevated in CMs. However, the
kit was unable to detect such concentrations, and further,
NAC treatment suppressed the observed diastolic dysfunc-
tion. NAC also suppressed cFos upregulation in PA-treatedcells. Thus, it is difficult to assess whether intracellular
ROS is altered by glucose or PA treatment and to determine
the precise role of ROS in DC. Current research shows a
mixed response in ROS production for cardiac cells treated
with HG. Although some studies report an increase in ROS
levels with 24 h glucose treatment (7,32), other studies
either show no significant response (33) or require addi-
tional supplements to generate a response (34).
In a similar way, increased expression of the thioredoxin
interacting protein (TXNIP) was shown to increase oxida-
tive stress by inhibiting thioredoxin, a protein that modu-
lates the cellular redox state (35,36). Chen et al. found
that HG increases TXNIP levels in H9C2 cells, which
serve as an immortal analog for cardiac myocytes (37). In
addition, NAC has been found to reduce glucose-inducedBiophysical Journal 106(11) 2322–2329
2328 Michaelson et al.upregulation of TXNIP in pancreatic b cells (7). However,
we found that HG treatment does not have a significant ef-
fect on TXNIP levels in CMs, suggesting that this pathway
may also have a limited effect in DC (Fig. S2).
The use of microrheology is advantageous in describing
the passive properties of cells. However, whether the
increase in cell stiffness contributes to overall cardiac stiff-
ening is yet to be determined. In a similar way, spontaneous
contractile dysfunction may not be indicative of regulated
beating patterns. Interestingly, microrheological responses
to PA and elevated glucose exhibited a frequency-dependent
effect, with low frequencies (high time lags) typically exhib-
iting the largest effects. This result suggests that changes
to properties (usually stiffening under diabetic conditions)
affect the slower characteristics of the cells to a greater
extent than the faster responses, such as those during
contractions.
In comparing mechanical properties of cells under
different conditions, we also attempted microrheological
measurements after NAC dosing, but the results were very
variable, with cardiac myocytes isolated from different
litters yielding different MSDs. This effect may be due to
the variability inherent in working with primary cells or to
the number of conditions being altered at the same time. It
is also possible that NAC has nonlinear effects on cell prop-
erties that are not readily modeled using currently available
methods. However, we believe that it would be productive
to examine the use of antioxidants in modulating the
maladaptive alterations in DC-model cell stiffness and
hypertrophy in future studies. In a similar way, it may prove
fruitful to use combinations of glucose, PA, and ROS,
although care must be taken to temper cell stresses. Finally,
the differences presented in this article between AFM and
microrheology may be due to characteristics of the regions
being probed, with AFM yielding cell cortical properties
and micorheology yielding internal cytoplasmic properties.
Use of other methods to probe biomechanical properties
may be helpful. Further establishing and clarifying molecu-
lar links and pathways would also likely be useful mecha-
nistic complements to in vivo studies.
Our main conclusions from this study are that 1), diabetic
conditions result in changes to cell properties consistent with
DC; 2), glucose, PA, and ROS dosing influence different cell
properties; and 3), the ROS effect on cells can occur at con-
centrations that are generally difficult to measure. Thus, the
use of bioengineering tools to examine cell properties can
offer useful information in understanding DC progression.SUPPORTING MATERIAL
Twofigures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(14)00458-5.
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